Hengrui Shares Rise on $2.6 Billion Novo Nordisk Obesity Drug Deal 
Lindt Slashes 2026 Sales Growth Forecast as European Demand Weakens 
Robinhood Chain Token Ring Allegedly Extracts $18.4 Million Across 53 Launches 
Goldman Sachs Eyes John Waldron as CEO Successor 
Toyota Global Sales Fall for Seventh Month as China Demand Slumps 
Franklin Templeton Partners With Bybit for Tokenized Fund Collateral 
Binance Expands MarsCoin With Tokenized SpaceX Share Rewards 
Pepco Raises FY26 Earnings Outlook, Unveils €400 Million Buyback 
OpenAI Scraps GPT-6.1 Astra Launch Over Safety Concerns 
Bitget Restores Withdrawals After $388 Million Security Breach 
QNT Whales Move $10M to Exchanges After 400% Rally 
BlackRock’s Rick Rieder Favors Bonds Over Stocks as Treasury Yields Surge 
Chainlink Launches CCIP 2.0 With Enhanced Cross-Chain Security 
Stellar Hits Record 217 TPS as Institutional RWA Activity Surges 
Vitalik Buterin Says Hegota Could Be Ethereum’s Last Conventional Fork 
Samsung Invests $1 Billion in KKR’s Helix AI Infrastructure 
Bitget Resumes Crypto Withdrawals After $388M Security Breach 
Add as a preferred source on Google
CAMBRIDGE, Mass., Feb. 09, 2017 -- Cellaria, LLC, a scientific innovator that develops revolutionary new patient-specific cancer models for challenging tumors, today announced the formation of a strategic partnership with AMS Biotechnology (AMSBIO). As part of the agreement, AMSBIO will distribute, market and sell Cellaria cell models and culture media throughout Europe. The partnership enables Cellaria to better meet growing demand for its products outside the US.
Cellaria's unique patient-specific cell models and cell culture media products expand the current offering AMSBIO has for physiologically relevant cell culture products for drug discovery and other life science applications. Late in 2016, Cellaria announced the availability of new models for High Grade Serous and Endometriod Ovarian Cancer and an ER-positive breast model.
AMSBIO is a premier provider of quality life science research reagents and services helping customers develop innovative methods, processes, products and medicines. As a leading provider of scaffolds, matrices, kits and proteins for growing and screening spheroids and organoids, AMSBIO has contributed to the acceleration of discovery programs in medical research.
Alex Sim, managing director at AMSBIO said, "The new partnership with Cellaria expands our existing portfolio by introducing patient-derived cancer models; allowing customers to conduct research and drug discovery initiatives to advance precision medicine.”
"The unique value of our patient-specific cell models makes AMSBIO an ideal partner for Cellaria," said David Deems, chief executive officer at Cellaria. "Our products will expand the AMSBIO cancer product portfolio, and their technical expertise will enable them to support Cellaria's customers throughout Europe."
About Cellaria
Cellaria creates breakthrough oncology models that reflect the unique nature and complexity of a tumor. Using these informative models, cancer researchers are better able to select promising compounds and work towards personalized approaches that would enable physicians to identify the most effective treatment for each patient's needs. Cellaria's innovative products help lead the research community to more personalized therapeutics, revolutionizing and accelerating the search for a cancer cure. For more information, visit www.cellariabio.com or to learn more about our cell models.
Contact: Tim Walsh for Cellaria Bio 617.512.1641 [email protected]
